

# Stephen J Greene

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10408337/publications.pdf>

Version: 2024-02-01

207  
papers

9,804  
citations

46918

47  
h-index

43802

91  
g-index

209  
all docs

209  
docs citations

209  
times ranked

10440  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Global Health and Economic Burden of Hospitalizations for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1123-1133.	1.2	1,640
2	Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 351-366.	1.2	775
3	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	6.1	525
4	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
5	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	3.8	297
6	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	3.8	288
7	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	1.9	265
8	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015, 12, 220-229.	6.1	238
9	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. <i>JAMA Cardiology</i> , 2018, 3, 1011.	3.0	146
10	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. <i>Circulation Research</i> , 2017, 120, 332-340.	2.0	144
11	The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2013, 2, e000536.	1.6	131
12	Prevalence and prognostic impact of noncardiac comorbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , 2018, 20, 1257-1266.	2.9	130
13	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , 2021, 6, 743.	3.0	125
14	Haemoconcentration, renal function, and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	2.9	119
15	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	1.7	118
16	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008335.	1.6	113
17	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019, 7, 1-12.	1.9	109
18	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012, 14, 1056-1066.	2.9	105

#	ARTICLE	IF	CITATIONS
19	Outpatient Worsening Heart Failure as a Target for Therapy. <i>JAMA Cardiology</i> , 2018, 3, 252.	3.0	90
20	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	1.2	90
21	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
22	Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. <i>American Heart Journal</i> , 2013, 165, 216-225.	1.2	82
23	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. <i>JAMA Cardiology</i> , 2020, 5, 714.	3.0	76
24	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3298-3309.	1.4	76
25	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013, 15, 551-559.	2.9	75
26	Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials. <i>American Heart Journal</i> , 2021, 232, 10-22.	1.2	75
27	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	1.2	72
28	The disconnect between phase II and phase III trials of drugs for heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 85-97.	6.1	69
29	Population Risk Prediction Models for Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 438-447.	1.6	69
30	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69
31	Trends in prevalence of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 1032-1042.	2.9	68
32	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
33	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522.	3.0	62
34	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	2.9	60
35	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2013, 1, 488-496.	1.9	58
36	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 591-600.	2.9	58

#	ARTICLE	IF	CITATIONS
37	Medication dosing for heart failure with reduced ejection fraction " opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
38	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Failure Reviews, 2016, 21, 95-102.	1.7	55
39	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circulation: Heart Failure, 2020, 13, e006605.	1.6	55
40	Prognostic Significance of Serum Total Cholesterol and Triglyceride Levels in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2013, 111, 574-581.	0.7	54
41	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq1 1 00784314 18BT /Ov	0.7	54
42	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	1.0	53
43	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	2.9	52
44	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure, 2017, 4, 402-408.	1.4	50
45	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2018, 71, 1379-1390.	1.2	50
46	Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 2038-2047.	1.2	49
47	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	1.7	48
48	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
49	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	1.2	48
50	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	47
51	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	1.9	47
52	Risk Profiles in Heart Failure. Circulation: Heart Failure, 2020, 13, e007132.	1.6	44
53	Hemoconcentration-guided Diuresis in Heart Failure. American Journal of Medicine, 2014, 127, 1154-1159.	0.6	43
54	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2018, 20, 304-314.	2.9	42

#	ARTICLE	IF	CITATIONS
55	Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. <i>American Heart Journal</i> , 2018, 204, 163-173.	1.2	42
56	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
57	Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008685.	1.6	39
58	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 199.	0.7	38
59	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. <i>American Heart Journal</i> , 2021, 233, 86-91.	1.2	38
60	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
61	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 20.	2.7	36
62	Natriuretic peptide-guided management in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 556-568.	0.6	35
63	The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , 2018, 20, 963-972.	2.9	35
64	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
65	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
66	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	2.9	33
67	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	2.9	30
68	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 98-108.	2.9	30
69	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
70	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 826-836.	0.7	30
71	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 292.	3.0	28
72	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. <i>American Heart Journal</i> , 2017, 186, 130-138.	1.2	27

#	ARTICLE	IF	CITATIONS
73	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 122.	1.2	27
74	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , 2020, 8, 943-953.	1.9	26
75	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	1.9	26
76	Quadruple Medical Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1408-1411.	1.2	26
77	In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. <i>European Journal of Heart Failure</i> , 2022, 24, 227-229.	2.9	26
78	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380.	0.7	25
79	Matching Mechanism of Death With Mechanism of Action. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1599-1601.	1.2	24
80	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
81	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
82	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , 2022, 243, 103-109.	1.2	24
83	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	0.7	23
84	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	2.9	23
85	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 159-161.	0.7	23
86	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
87	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
88	Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179.	0.7	22
89	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
90	Pragmatic Design of Randomized Clinical Trials for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 325-335.	1.9	22

#	ARTICLE	IF	CITATIONS
91	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1488-1498.	2.9	22
92	Contextualizing Risk Among Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2261.	3.8	22
93	The need for increased pragmatism in cardiovascular clinical trials. <i>Nature Reviews Cardiology</i> , 2022, 19, 737-750.	6.1	22
94	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 677-686.	2.9	21
95	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. <i>JACC: Heart Failure</i> , 2022, 10, 350-362.	1.9	21
96	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	20
97	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 266-275.	1.9	20
98	Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1101-1103.	1.2	19
99	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
100	Clinical inertia and medical therapy for heart failure: the unintended harms of "first, do no harm". <i>European Journal of Heart Failure</i> , 2021, 23, 1343-1345.	2.9	19
101	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 876-886.	1.9	19
102	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021, 6, 1415.	3.0	19
103	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , 2018, 20, 1068-1071.	2.9	17
104	The Potential Role of Natriuretic Peptide-Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239.	0.7	16
105	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2021, 27, 2-19.	0.7	16
106	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384.	0.7	16
107	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
108	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15

#	ARTICLE	IF	CITATIONS
109	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	15
110	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	15
111	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	0.6	15
112	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. <i>ESC Heart Failure</i> , 2022, 9, 947-952.	1.4	15
113	Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2012, 110, 1657-1662.	0.7	14
114	Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. <i>European Journal of Heart Failure</i> , 2015, 17, 875-878.	2.9	14
115	Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. <i>European Journal of Heart Failure</i> , 2019, 21, 121-124.	2.9	14
116	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	1.7	13
117	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
118	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. <i>JACC: Heart Failure</i> , 2019, 7, 267-271.	1.9	13
119	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 741-753.	1.7	13
120	Drugs of Abuse and Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1260-1275.	0.7	13
121	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346.	0.7	12
122	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
123	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	0.8	11
124	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25.	1.4	11
125	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
126	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 47-55.	1.9	10



#	ARTICLE	IF	CITATIONS
127	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	1.6	10
128	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	0.8	9
129	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	1.2	9
130	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , 2018, 20, 1379-1381.	2.9	9
131	The Urgency of Doing. <i>JACC: Heart Failure</i> , 2019, 7, 22-24.	1.9	9
132	The Maximally Tolerated Dose. <i>JACC: Heart Failure</i> , 2020, 8, 739-741.	1.9	9
133	Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of “too little, too late”. <i>European Journal of Heart Failure</i> , 2021, 23, 1514-1517.	2.9	9
134	Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008943.	1.6	9
135	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
136	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 714-717.	1.9	8
137	The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008030.	1.6	8
138	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
139	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	1.2	8
140	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 145, 165-168.	0.7	8
141	Trends in Characteristics and Outcomes of Peripartum Cardiomyopathy Hospitalizations in the United States Between 2004 and 2018. <i>American Journal of Cardiology</i> , 2022, 168, 142-150.	0.7	8
142	Recognizing the Significance of Outpatient Worsening Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017485.	1.6	7
143	The real world of <i>de novo</i> heart failure: the next frontier for heart failure clinical trials?. <i>European Journal of Heart Failure</i> , 2020, 22, 1786-1789.	2.9	7
144	Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. <i>European Journal of Heart Failure</i> , 2021, 23, 1525-1528.	2.9	7

#	ARTICLE	IF	CITATIONS
145	Classifying heart failure based on ejection fraction: imperfect but enduring. <i>European Journal of Heart Failure</i> , 2022, 24, 1154-1157.	2.9	7
146	Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. <i>European Journal of Heart Failure</i> , 2016, 18, 1190-1192.	2.9	6
147	Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 283-290.	0.6	6
148	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018, 15, 10-16.	1.3	6
149	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607.	1.7	6
150	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	0.7	6
151	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , 2020, 220, 97-107.	1.2	6
152	Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. <i>American Heart Journal</i> , 2020, 230, 25-34.	1.2	6
153	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021, 8, 26-36.	1.4	6
154	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
155	An evaluation of torsemide in patients with heart failure and renal disease. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 5-11.	0.6	6
156	Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. <i>JAMA Network Open</i> , 2022, 5, e220035.	2.8	6
157	Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America. <i>Heart Failure Clinics</i> , 2015, 11, 581-589.	1.0	5
158	Considering the duration of heart failure: using the past to predict the future. <i>European Journal of Heart Failure</i> , 2018, 20, 382-384.	2.9	5
159	In-hospital outcomes after bariatric surgery in patients with heart failure. <i>American Heart Journal</i> , 2020, 230, 59-62.	1.2	5
160	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	1.4	5
161	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 916-923.	0.7	5
162	Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. <i>American Heart Journal</i> , 2022, 251, 127-136.	1.2	5

#	ARTICLE	IF	CITATIONS
163	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , 2017, 248, 414-420.	0.8	4
164	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
165	Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3176-3178.	1.2	4
166	Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. <i>European Journal of Heart Failure</i> , 2020, 22, 1019-1021.	2.9	4
167	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 111-116.	2.3	4
168	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
169	Robustness of outcomes in trials evaluating sodium-glucose cotransporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
170	Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. <i>American Heart Journal</i> , 2022, 251, 115-126.	1.2	4
171	Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2015, 17, 991-993.	2.9	3
172	REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study. <i>European Journal of Heart Failure</i> , 2015, 17, 472-474.	2.9	3
173	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , 2015, 20, 393-400.	1.7	3
174	Hospitalized Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 591-601.	1.0	3
175	Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2020, 22, 164-167.	2.9	3
176	Improving In-Hospital Diuretic Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 709-712.	1.2	3
177	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2021, 27, 1175-1184.	0.7	3
178	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. <i>American Journal of Medicine</i> , 2014, 127, 574-578.	0.6	2
179	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015, 116, 307-312.	0.7	2
180	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1061-1062.	1.2	2

#	ARTICLE	IF	CITATIONS
181	Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 870-872.	2.9	2
182	Protein turnover in the failing heart: an ever-changing landscape. <i>European Journal of Heart Failure</i> , 2017, 19, 1218-1221.	2.9	2
183	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1760-1763.	2.9	2
184	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1426-1427.	1.2	2
185	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
186	Physical Functioning in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 1002-1016.	0.7	2
187	Prioritizing prevention of <i>de novo</i> and worsening chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 653-656.	2.9	2
188	Dual Antiplatelet Therapy After Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1446.	3.8	1
189	Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 41-44.	1.2	1
190	Reframing Global Variation in Heart Failure Trials. <i>JACC: Heart Failure</i> , 2019, 7, 347-349.	1.9	1
191	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. <i>Journal of Cardiac Failure</i> , 2021, 27, 607-609.	0.7	1
192	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. <i>American Heart Journal</i> , 2021, 233, 1-4.	1.2	1
193	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	1.7	1
194	Sodium-glucose cotransporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. <i>European Journal of Heart Failure</i> , 2021, 23, 1023-1025.	2.9	1
195	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. <i>Current Heart Failure Reports</i> , 2021, 18, 132-143.	1.3	1
196	Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , 2021, 14, e008147.	1.6	1
197	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	0.7	1
198	Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 649-652.	1.9	1

#	ARTICLE	IF	CITATIONS
199	Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032.		1
200	Investigator-Reported Versus Adjudicated Clinical Events. Journal of the American College of Cardiology, 2021, 78, 1538-1540.	1.2	1
201	Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States Between 2005-2018. American Journal of the Medical Sciences, 2022, 363, 459-461.	0.4	1
202	Influence of Chronic Kidney Disease on Warfarin Therapy for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 311, 2541.	3.8	0
203	Bulletproof heart: Gunshot wound to the ventricular septum without pericardial effusion or hemodynamic collapse. Canadian Journal of Emergency Medicine, 2018, 20, S40-S40.	0.5	0
204	Real-World Evidence for Medication Safety. JACC: Heart Failure, 2019, 7, 846-848.	1.9	0
205	Breaking Clinical Inertia in Heart Failure Management. Joint Commission Journal on Quality and Patient Safety, 2021, , .	0.4	0
206	Annals for Hospitalists Inpatient Notes - Clinical Pearls“Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, HO2-HO3.	2.0	0
207	Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial. Circulation, 2017, 136, .	1.6	0